More articles from Review
- The case for more aggressive screening and treatment of mild thyroid failure
What do you do if a patient has mildly elevated TSH but normal T4 and T3 levels?
- How to use nesiritide in treating decompensated heart failure
Nesiritide, a recombinant formulation of BNP, is the first new parenteral drug in more than a decade to be approved for treating heart failure.
- The B-type natriuretic peptide assay: A rapid test for heart failure
This 15-minute test is highly sensitive and fairly specific and is useful in evaluating suspected heart failure in outpatients and in emergency care.
- Hereditary hemochromatosis: A common, often unrecognized, genetic disease
Although hereditary hemochromatosis is one of the most common genetic diseases affecting people of northern European descent, it is underdiagnosed.
- Chronic tension-type headache: Advice for the viselike-headache patient
About 3% of people complain of daily viselike headaches without associated symptoms. Therapy consists of tricyclic antidepressants, biofeedback, and stress management, although solid data are lacking.
- Tired, aching, ANA-positive: Does your patient have lupus or fibromyalgia?
Do not rely on the antinuclear antibody test to make the distinction between fibromyalgia and lupus.
- Idiopathic retroperitoneal fibrosis: Prompt diagnosis preserves organ function
The chief dangers from idiopathic retroperitoneal fibrosis— ureteral obstruction with loss of renal function, and other organ involvement—are avoidable and treatable with prompt diagnosis.
- Advances in treatment of chronic hepatitis C: ‘Pegylated’ interferons
New formulations of interferon alfa that incorporate polyethylene glycol in the drug molecule are an important advance in the treatment of chronic hepatitis C.
- A primer on referring patients for psychotherapy
With many models of psychotherapy available, finding a good fit between therapist and patient is crucial.
Sepsis: Menu of new approaches replaces one therapy for allRecombinant human activated protein C is the first therapy approved for treating sepsis. However, instead of a “one therapy for all” approach, we are finding that therapy must be targeted.
